Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo

Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World
                           Vaccine Congress & Expo

-- Efficacy and Safety Data for EV71 Vaccine Discussed in Presentation by
Deputy Director of Jiangsu Provincial CDC

PR Newswire

BEIJING, April 18, 2013

BEIJING, April 18, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a
leading provider of vaccines in China, announced today that Fengcai Zhu,
Deputy Director of the Jiangsu Provincial Center for Disease Prevention and
Control, presented data regarding Sinovac's proprietary enterovirus 71
("EV71") vaccine against hand, foot and mouth disease ("HFMD") at the 13th
Annual World Vaccine Congress & Expo, taking place from April 16-18, 2013, in
Washington D.C.Dr. Fengcai Zhu acted as a co-principal investigator in
Sinovac's phase III trial for its EV71 vaccine.

Dr. Fengcai Zhu delivered a presentation entitled "The clinical evaluation of
new vaccines in China," at 12:25 pm EDT on April 17, 2013.In his
presentation, Dr. Fengcai Zhu discussed the efficacy and safety of the
Company's EV71 vaccine. Data from the Phase III trial indicated that our EV71
vaccine had 95% efficacy against EV71-associated HFMD /herpangina, and 100%
efficacy against EV71-associated hospitalization. Herpangina is a painful
mouth infection that can be caused by EV71.

There were no significant differences between the vaccine group and the
placebo group for the adverse reaction symptoms and incident rate in the phase
III trial.

The double-blinded, randomized, placebo controlled phase III clinical trial
was conducted at three sites across China's Jiangsu province. Approximately
10,000 healthy infants completed the two-dose vaccination schedule (at day 0
and day 28) in the first quarter of 2012, prior to the HFMD epidemic season in
China. Trial participants were then followed in an active monitoring period.

For more information about the 13th Annual World Vaccine Congress & Expo,
visit the webpage
(http://www.terrapinn.com/2013/world-vaccine-congress-washington/index.stm) or
the event blog (http://blogs.terrapinn.com/vaccinenation).

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on research, development, manufacturing and commercialization of vaccines that
protect against human infectious diseases including hepatitis A and B,
seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal
rabies vaccine. In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for
the Chinese Central Government, pursuant to the government-stockpiling
program. The Company is also the only supplier of the H5N1 pandemic influenza
vaccine to the government-stockpiling program. Sinovac is developing a number
of new pipeline vaccines including vaccines for enterovirus 71 (against hand,
foot, and mouth disease), pneumococcal conjugate, pneumococcal
polysaccharides, varicella and rubella. Sinovac sells its vaccines mainly in
China and exports selected vaccines to Mongolia, Nepal, and the Philippines.
Sinovac was also granted a license to commercialize seasonal flu vaccine in
Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.

Helen Yang
Sinovac Biotech Ltd.
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com

Media:
Aaron Estrada
The Ruth Group
Tel: +1-646-536-7028
Email: aestrada@theruthgroup.com

SOURCE Sinovac Biotech Co., Ltd.

Website:
http://www.terrapinn.com/2013/world-vaccine-congress-washington/index.stm
Website: http://blogs.terrapinn.com/vaccinenation
 
Press spacebar to pause and continue. Press esc to stop.